GlassScriptPhysician profile
Ray Bauer Vaughters
NPI 1457327587
$321,058.46
in general payments reported to CMS, 2019-2025
57 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what 77% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108K · 2020: $66K · 2021: $62K · 2022: $74K · 2023: $7,600 · 2024: $1,159 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,600 · Food and Beverage: $4,863 · Education: $310 · Travel and Lodging: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,600.00 |
| Food and Beverage | $4,863.21 |
| Education | $310.43 |
| Travel and Lodging | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $109,188.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $96,195.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $71,414.36 | 2019-2022 | |
| Mannkind Corporation | $34,371.64 | 2019-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $1,396.30 | 2019-2025 | |
| Corcept Therapeutics | $998.99 | 2019-2025 | Korlym |
| Amgen INC. | $954.09 | 2019-2024 | Evenity, Prolia, Tepezza |
| Xeris Pharmaceuticals, INC. | $766.20 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Dexcom, INC. | $705.18 | 2019-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $541.14 | 2019-2021 | |
| Antares Pharma, INC. | $487.66 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Beta Bionics, INC. | $370.76 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Horizon Therapeutics Plc | $321.92 | 2021-2023 | Tepezza |
| Radius Health, INC. | $275.76 | 2019-2023 | |
| Insulet Corporation | $267.60 | 2019-2025 | Omnipod |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ray Vaughters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.